| Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis AR Mato, C Nabhan, MC Thompson, N Lamanna, DM Brander, B Hill, ... Haematologica 103 (5), 874, 2018 | 463 | 2018 |
| Outcomes of COVID-19 in patients with CLL: a multicenter international experience AR Mato, LE Roeker, N Lamanna, JN Allan, L Leslie, JM Pagel, K Patel, ... Blood, The Journal of the American Society of Hematology 136 (10), 1134-1143, 2020 | 324 | 2020 |
| Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients AR Mato, BT Hill, N Lamanna, PM Barr, CS Ujjani, DM Brander, C Howlett, ... Annals of Oncology 28 (5), 1050-1056, 2017 | 271 | 2017 |
| The human PD-1 gene: complete cDNA, genomic organization, and developmentally regulated expression in B cell progenitors LR Finger, J Pu, R Wasserman, R Vibhakar, E Louie, RR Hardy, ... Gene 197 (1-2), 177-187, 1997 | 238 | 1997 |
| Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience AR Mato, C Nabhan, PM Barr, CS Ujjani, BT Hill, N Lamanna, ... Blood, The Journal of the American Society of Hematology 128 (18), 2199-2205, 2016 | 223 | 2016 |
| Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States AR Mato, M Thompson, JN Allan, DM Brander, JM Pagel, CS Ujjani, ... Haematologica 103 (9), 1511, 2018 | 179 | 2018 |
| Paroxysmal nocturnal hemoglobinuria from bench to bedside JJ Pu, RA Brodsky Clinical and translational science 4 (3), 219-224, 2011 | 129 | 2011 |
| Assessment of the efficacy of therapies following venetoclax discontinuation in CLL reveals BTK inhibition as an effective strategy AR Mato, LE Roeker, R Jacobs, BT Hill, N Lamanna, D Brander, ... Clinical Cancer Research 26 (14), 3589-3596, 2020 | 125 | 2020 |
| PD-1 pathway and its clinical application: A 20 year journey after discovery of the complete human PD-1 gene KN Berger, JJ Pu Gene 638, 20-25, 2018 | 117 | 2018 |
| Natural history of paroxysmal nocturnal hemoglobinuria clones in patients presenting as aplastic anemia JJ Pu, G Mukhina, H Wang, WJ Savage, RA Brodsky European journal of haematology 87 (1), 37-45, 2011 | 111 | 2011 |
| Alternative Polyadenylation: a new frontier in post transcriptional regulation F Ren, N Zhang, L Zhang, E Miller, JJ Pu Biomarker Research 8, 1-10, 2020 | 83 | 2020 |
| Outcomes of front‐line ibrutinib treated CLL patients excluded from landmark clinical trial AR Mato, LE Roeker, JN Allan, JM Pagel, DM Brander, BT Hill, ... American journal of hematology 93 (11), 1394-1401, 2018 | 71 | 2018 |
| COVID-19 in patients with CLL: improved survival outcomes and update on management strategies LE Roeker, TA Eyre, MC Thompson, N Lamanna, AR Coltoff, MS Davids, ... Blood, The Journal of the American Society of Hematology 138 (18), 1768-1773, 2021 | 66 | 2021 |
| Mantle cell lymphoma and its management: where are we now? A Ladha, J Zhao, EM Epner, JJ Pu Experimental Hematology & Oncology 8, 1-9, 2019 | 54 | 2019 |
| Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting JZ Hou, JC Ye, JJ Pu, H Liu, W Ding, H Zheng, D Liu Journal of Hematology & Oncology 14, 1-25, 2021 | 51 | 2021 |
| Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy AR Mato, N Ghosh, SJ Schuster, N Lamanna, JM Pagel, IW Flinn, ... Blood, The Journal of the American Society of Hematology 137 (20), 2817-2826, 2021 | 49 | 2021 |
| Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies VV Prabhu, MK Talekar, AR Lulla, CLB Kline, L Zhou, J Hall, ... Cell Cycle 17 (4), 468-478, 2018 | 47 | 2018 |
| The small population of PIG-A mutant cells in myelodysplastic syndromes do not arise from multipotent hematopoietic stem cells JJ Pu, R Hu, GL Mukhina, HE Carraway, MA McDevitt, RA Brodsky Haematologica 97 (8), 1225, 2012 | 40 | 2012 |
| Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen MC Thompson, RA Harrup, CC Coombs, LE Roeker, JJ Pu, MY Choi, ... Blood advances 6 (15), 4553-4557, 2022 | 39 | 2022 |
| Cloning and structural characterization of ECTACC, a new member of the transforming acidic coiled coil (TACC) gene family: cDNA sequence and expression analysis in human … JJ Pu, C Li, M Rodriguez, D Banerjee Cytokine 13 (3), 129-137, 2001 | 31 | 2001 |
